This bill seeks to nullify the FDA’s 2023 modifications to the risk evaluation and mitigation strategy for the abortion medication mifepristone and prohibits the implementation of similar future requirements.
Diana Harshbarger
Representative
TN-1
This bill seeks to nullify the Food and Drug Administration’s January 2023 modifications to the risk evaluation and mitigation strategy (REMS) for the abortion medication mifepristone. Additionally, it prohibits the Secretary of Health and Human Services from implementing any future safety requirements that are substantially similar to those nullified changes.
New Bill Reverses FDA Rules for Mifepristone: January 2023 Safety Changes Set for Nullification
This bill takes a direct aim at the pharmacy counter by nullifying the FDA’s January 2023 updates to the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, a drug used for early pregnancy termination. By wiping these specific modifications off the books, the legislation effectively rolls back the safety protocols to their pre-2023 state. Furthermore, it places a permanent “do not enter” sign for the Secretary of Health and Human Services, prohibiting the creation or enforcement of any future safety rules that are “substantially similar” to the ones being canceled today.
Rolling Back the Pharmacy Clock
Under the 2023 FDA changes, the rules were modified to allow retail pharmacies to dispense mifepristone if they met certain certification standards, rather than requiring the drug to be dispensed only in clinics or hospitals. This bill’s nullification of those changes means the legal landscape for how and where you can pick up this medication would shift back. For a patient in a rural area who previously could have used a local certified pharmacy, this change might mean a much longer drive to a specific clinic or hospital that is authorized to hand over the medication under the older, stricter REMS framework.
The Future of Safety Oversight
A major provision in this bill prevents the government from ever implementing “substantially similar” requirements in the future. In the world of medical regulation, this is a significant move because it limits the FDA’s ability to adjust safety protocols based on new data or clinical outcomes. If you’re a healthcare provider, this creates a rigid regulatory environment where the rules for this specific drug are essentially frozen in time, regardless of what new medical research might suggest about the best way to handle patient safety or drug distribution.
Impact on the Regulatory Guardrails
By targeting the REMS—which is the FDA’s primary tool for managing drugs with known serious safety concerns—the bill shifts the balance of power between lawmakers and scientists. For the average person, this means the “fine print” on how this medication is managed is being rewritten by legislation rather than regulatory review. While some may see this as a necessary correction of agency overreach, others may worry about the precedent of bypassing the FDA’s expert-led process for determining how medications should be safely distributed to the public.